Atrial fibrillation (AF) is often asymptomatic, increases stroke risk and can be treated with anticoagulation – so the logic of screening seems compelling. New patches, loop recorders and smartwatches promise to detect hidden fibrillation before the first stroke occurs. However, the randomized AMALFI study presented at ESC Congress 2025 joins a series of high-quality investigations showing a sobering pattern: more technology detects more atrial fibrillation – but with hardly any reduction in strokes. This article places AMALFI in the context of the evidence and asks why the gap between detection and clinical benefit is so persistent.
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D
SGLT2i, metformin, or both?
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing